IMMUNOREGULATORY CIRCUITS IN MAN
人类的免疫调节回路
基本信息
- 批准号:6374875
- 负责人:
- 金额:$ 7.27万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1985
- 资助国家:美国
- 起止时间:1985-07-01 至 2001-09-22
- 项目状态:已结题
- 来源:
- 关键词:CD antigens Sjogren's syndrome T lymphocyte autoradiography biological signal transduction cell migration cytokine enzyme linked immunosorbent assay gene expression human subject immunoregulation laboratory mouse leukocyte activation /transformation phosphorylation protein biosynthesis protein tyrosine kinase rheumatoid arthritis systemic lupus erythematosus tissue /cell culture
项目摘要
DESCRIPTION (Adapted from Investigator's abstract): Memory CD4 T-cells play
a key role in host defense as well as the triggering and maintaining of
inflammation. The triggering of the costimulatory signals plays a central
role in the generation of effective immune responses. The costimulatory
signals can be provided by a number of accessory molecules. Of the
costimulatory molecules, CD29/VLA, CD26, and CD27 have been established by
this group. CD29/VLA and CD26 are preferentially expressed on CD4 memory
T-cells and play an important role in the costimulation, function, and
migration of memory T-cells. Much remains to be clarified regarding the
complex functions of CD29/VLA and CD26 in signal transduction and the
subsequent effects upon T-cell function and cell migration. The major goal
of this application is to determine the immunoregulatory circuits in man.
The specific aims of this application are: 1) The molecular basis of
CD29/VLA in T-cell costimulation, signaling and T-cell function. They will
define the structural basis of Cas-L tyrosine phosphorylation and FAK
activation and define the role of Cas-L in CD29/VLA-mediated cytokine
production and gene expression. Moreover, the role of Cas-L in T-cell
migration will be defined. 2) The molecular basis of CD26/DPPIV in T-cell
function and costimulation. The role of CD26/DPPIV in T-cell migration, the
precise characteristics of the binding of ADA to CD26, and the functional
significance of ADA in T-cell activation will be defined. In addition, the
structure and function of the ligand of CD26 other than ADA will be defined.
3), The molecular and cellular defects in patients with autoimmune diseases.
Analysis of VLA-mediated costimulation in patients with autoimmune diseases
will be performed. Moreover, the expression and function, of Cas-L, and FAK
as well as the migratory activity of T-cells in autoimmune diseases will be
determined. In addition, the level of CD26/DPPIV in serum/plasma and its
correlation with clinical complications in autoimmune diseases will be
defined. The study will not only provide new insights into understanding of
the mechanisms of T-cell activation and migration, but will also provide new
insights into understanding the precise molecular mechanisms of immune
abnormalities found in various autoimmune diseases and will lead to the
development of rational therapy for the manipulation of the abnormalities
found in such diseases.
描述(改编自研究者的摘要):记忆CD4 t细胞发挥作用
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Chikao Morimoto其他文献
Chikao Morimoto的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Chikao Morimoto', 18)}}的其他基金
CHARACTERIZATION OF IMMUNOREGULATORY T CELLS POST ALLOGENIC BMT
同种异体 BMT 后免疫调节 T 细胞的表征
- 批准号:
6099462 - 财政年份:1998
- 资助金额:
$ 7.27万 - 项目类别:
CHARACTERIZATION OF IMMUNOREGULATORY T CELLS POST ALLOGENIC BMT
同种异体 BMT 后免疫调节 T 细胞的表征
- 批准号:
6234962 - 财政年份:1997
- 资助金额:
$ 7.27万 - 项目类别:
STRUCTURE AND FUNCTION OF THE HUMAN DPPIV/CD26 MOLECULE
人 DPPIV/CD26 分子的结构和功能
- 批准号:
2096730 - 财政年份:1993
- 资助金额:
$ 7.27万 - 项目类别:
STRUCTURE AND FUNCTION OF THE HUMAN DPPIV/CD26 MOLECULE
人 DPPIV/CD26 分子的结构和功能
- 批准号:
3200109 - 财政年份:1993
- 资助金额:
$ 7.27万 - 项目类别:
STRUCTURE AND FUNCTION OF THE HUMAN DPPIV/CD26 MOLECULE
人 DPPIV/CD26 分子的结构和功能
- 批准号:
2096731 - 财政年份:1993
- 资助金额:
$ 7.27万 - 项目类别:
CHARACTERIZATION OF THE IMMUNOREGULATORY CIRCUITS IN MAN
人类免疫调节回路的特征
- 批准号:
3156633 - 财政年份:1985
- 资助金额:
$ 7.27万 - 项目类别:
CHARACTERIZATION OF THE IMMUNOREGULATORY CIRCUITS IN MAN
人类免疫调节回路的特征
- 批准号:
3156631 - 财政年份:1985
- 资助金额:
$ 7.27万 - 项目类别:
相似海外基金
Exploring Roles for Transcription Factor Ets1 in Sjogren's Syndrome
探索转录因子 Ets1 在干燥综合征中的作用
- 批准号:
10644080 - 财政年份:2023
- 资助金额:
$ 7.27万 - 项目类别:
Aging and Oxidative Stress Influence Salivary Gland Disease in Sjogren's Syndrome
衰老和氧化应激对干燥综合征唾液腺疾病的影响
- 批准号:
10682148 - 财政年份:2023
- 资助金额:
$ 7.27万 - 项目类别:
Controlling Autoimmune Inflammation and Promoting Salivary Gland Regeneration in Sjogren's Syndrome
控制干燥综合征的自身免疫炎症并促进唾液腺再生
- 批准号:
10528045 - 财政年份:2022
- 资助金额:
$ 7.27万 - 项目类别:
Harnessing molecular signatures to deliver personalised B-cell targeted therapies in Sjogren's syndrome
利用分子特征为干燥综合征提供个性化 B 细胞靶向治疗
- 批准号:
MR/X004694/1 - 财政年份:2022
- 资助金额:
$ 7.27万 - 项目类别:
Research Grant
Targeting Endogenous Mesenchymal Stromal Cells with Ruxolitinib to Treat Sialadenitis in Sjogren's Syndrome
用鲁索替尼靶向内源性间充质基质细胞治疗干燥综合征的唾液腺炎
- 批准号:
10646349 - 财政年份:2022
- 资助金额:
$ 7.27万 - 项目类别:
Targeting Endogenous Mesenchymal Stromal Cells with Ruxolitinib to Treat Sialadenitis in Sjogren's Syndrome
用鲁索替尼靶向内源性间充质基质细胞治疗干燥综合征的唾液腺炎
- 批准号:
10524424 - 财政年份:2022
- 资助金额:
$ 7.27万 - 项目类别:
Targeting P2 Receptors to Restore Salivary and Lacrimal Gland Function in Sjogren's Syndrome
靶向 P2 受体以恢复干燥综合征患者的唾液腺和泪腺功能
- 批准号:
10685136 - 财政年份:2022
- 资助金额:
$ 7.27万 - 项目类别:
Controlling Autoimmune Inflammation and Promoting Salivary Gland Regeneration in Sjogren's Syndrome
控制干燥综合征的自身免疫炎症并促进唾液腺再生
- 批准号:
10657745 - 财政年份:2022
- 资助金额:
$ 7.27万 - 项目类别:
Targeting P2 Receptors to Restore Salivary and Lacrimal Gland Function in Sjogren's Syndrome
靶向 P2 受体以恢复干燥综合征患者的唾液腺和泪腺功能
- 批准号:
10554383 - 财政年份:2021
- 资助金额:
$ 7.27万 - 项目类别: